Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MERCK SHARE OF MEDCO MAIL SERVICE IS ABOUT 21%, FIRM TELLS ANALYSTS; CHOLESTEROL, HYPERTENSION MEDICINES HAVE SHARES ABOUT 24 POINTS ABOVE NATIONAL AVERAGE

Executive Summary

Merck has a 21% dollar share of the Medco mail service business, Merck-Medco Managed Care President Per Lofberg told a securities analysts meeting at Merck's Whitehouse Station, N.J. headquarters Dec. 18.

You may also be interested in...



Abbott “Nominal Prices” Cited In Medco Suit; “Improper” Payments Alleged

Medco's access to "nominally priced" Abbott medicines is one example cited by the Philadelphia U.S. Attorney of an "inducement" accepted by the pharmacy benefit management company

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS029361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel